

05 Jun 2022 | News

Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast version of Five Must-Know Things: GSK boosts vaccine presence via M&A; US PBM formulary exclusions on the rise; ASCO data portend battle for bispecifics in lymphoma; mixed ASCO data for Cabometyx combos; and Junshi's oral COVID-19 antiviral shows promise although questions remain.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 3 June 2022, including: [*GlaxoSmithKline plc*](#) boosts vaccine presence via M&A; US PBM formulary exclusions on the rise; ASCO data portend battle for bispecifics in lymphoma; mixed ASCO data for Cabometyx combos; and [*Shanghai Junshi Biosciences Co., Ltd.*](#)'s oral COVID antiviral shows promise although questions remain.

This and all our other podcasts are available on the Informa Pharma Intelligence channel on [*Apple Podcasts*](#), [*Google Podcasts*](#), [*SoundCloud*](#), [*TuneIn*](#) and [*Spotify Podcasts*](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[*GSK Spies Pfizer Challenge With \\$2.1bn Vaccine Company Acquisition*](#)" - Scrip, 31 May, 2022.)

(Also see "[*PBM Formulary Exclusions On The Rise, PhRMA Says*](#)" - Scrip, 26 May, 2022.)

(Also see "[*ASCO Data Show A Battle Ahead For Roche And Genmab's Lymphoma Bispecifics*](#)" - Scrip, 27 May, 2022.)

(Also see "[*Exelixis's Cabometyx Plus Tecentriq Disappoints In Lung Cancer*](#)" - Scrip, 27 May, 2022.)

(Also see "[*Junshi's COVID Antiviral Superior To Paxlovid? Some Caveats Unveiled*](#)" - Scrip, 29 May, 2022.)

[Click here to explore this interactive content online](#) 